MNTA: That is partially my point: Why doesn't MNTA immediately expand their current M-118 trials with the assets they currently have? Or, would the cash drain be excessive given the entire pipeline cost? I view it as a positive dilemma, if M-118 works as hoped for. Perhaps they are waiting for data and/or other pipeline news such as M-Enox FDA pathway before making an election on the M-118 big picture.
Market Data 
Markets 
AI
